A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Friedreich Ataxia

In brief

The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).

Key facts

Study ID
NCT06681766
Run by
Larimar Therapeutics, Inc.
People needed
18
Starts
2024-12-06
Expected to finish
2025-04-27
Last updated by the study team
2026-07-10

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.